Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jul-Aug;27(4A):1897-900.

Serum markers to detect metastatic uveal melanoma

Vivian Barak  1 , Shachar Frenkel, Inna Kalickman, Andrew J Maniotis, Robert Folberg, Jacob Pe'er
Affiliations

Serum markers to detect metastatic uveal melanoma

Vivian Barak et al. Anticancer Res. 2007 Jul-Aug.

Abstract

Background: Osteopontin (OPN) is overexpressed in metastatic uveal melanoma (UM). S-100beta and melanoma-inhibitory activity (MIA) serum levels are elevated in metastatic cutaneous melanoma. The ability of OPN, S-100beta and MIA serum levels to be used as non-invasive markers for detecting metastatic UM was tested.

Patients and methods: OPN, S-100beta and MIA levels were measured by ELISA assays in 18 patients with metastatic UM and in 38 patients who were disease-free (DF) for at least 10 years after treatment of the primary tumor. Paired serum samples from 8 patients before and after development of metastasis were analyzed. Forty-four healthy controls (C) were compared to the other two groups.

Results: Serum OPN, MIA, and S-100beta levels were significantly higher in patients with metastatic UM as compared to patients who were DF for at least 10 years after treatment (p = 0.0001) or with age-matched controls. Serum OPN, MIA and S-100beta levels were significantly higher (p < 0.005) after metastasis formation than before the clinical detection of metastasis in the 8 patients. Receiver operator characteristic analysis was performed for metastatic patients vs. DF and vs. C, and the area under the curve was calculated for each marker and for the combination of the 3 markers, which was 91%.

Conclusion: Elevated serum OPN, MIA and S-100beta levels correlate with metastatic UM to the liver. When used in combination, these markers provide a highly sensitive and specific method to detect hepatic metastases and therefore provide for earlier therapeutic intervention that can prolong survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Serum levels of osteopontin –OPN (A), S-100β (B), and MIA (C) in gender and age-matched controls, patients who remained disease free ( DF) for at least 10 years after treatment for primary uveal melanoma, and patients who developed metastatic uveal melanoma to the liver. * Represents a statistically different level of marker as compared to the other groups.
Figure 2
Figure 2
Serum levels of osteopontin –OPN (A), S-100β (B), and MIA (C) before and after the detection of metastasis to the liver. * Represents a statistically different level of marker as compared to the other groups.
Figure 3
Figure 3
Serum levels of osteopontin- OPN , S100b and MIA recorded every 6 months on 2 patients (named DM, CM ) with uveal melanoma.
Figure 4
Figure 4
Receiver operator characteristic (ROC ) analysis performed on metastatic uveal melanoma compared to controls and to disease free patients.
See this image and copyright information in PMC

References

    1. Damato B. Developments in the management of uveal melanoma. Clinical and Experimental Ophthalmology. 2004;32:639–647. - PubMed
    1. Mudhar HS, Parsons MA, Sisley K, Rundle P, Singh A, Rennie IG. A critical appraisal of the prognostic and predictive factors for uveal malignant melanoma. Histopathol. 2004;45:1–12. - PubMed
    1. Kaiserman I, Amer R, Pe’er J. Liver function tests in metastatic uveal melanoma. Am J Ophthalmol. 2004;137(2):236–43. - PubMed
    1. Toivonen P, Makitie T, Kujala E, Kivela T. Microcirculation and tumor-infiltrating macrophages in choroidal and ciliary body melanoma and corresponding metastases. Investigative Ophthalmology and Visual Science. 2004;45:1–6. - PubMed
    1. Hannsson L, Hauschild A, Bonfrer JMG, Duffy J, Einarsson R. Tumor markers in malignant melanoma – EGTM (European Group on Tumor Markers) Guidelines. Tumor Biol. 2006;27:35 – S1.

Publication types